Promising Blood-Based Biomarkers for Melanoma: Recent Progress of Liquid Biopsy and Its Future Perspectives

Kanemaru, Hisashi; Mizukami, Yukari; Kaneko, Akira; Kajihara, Ikko; Fukushima, Satoshi

doi:10.1007/s11864-022-00948-2

Cited by 8 publications

(7 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early detection of relapses in the follow-up of patients undergoing treatment with targeted drugs is a situation that can benefit from the use of liquid biopsy, especially in patients with advanced melanoma. Treatment for melanoma has dramatically changed over the past decade with the introduction of immune checkpoint inhibitors and BRAF, plus MEK-targeted therapies into clinical practice [ 22 , 23 ]. Various studies have shown that liquid biopsy can be used to detect mutated BRAF, which can be identified in 32% of stage I/II patients and 39% of stage III/IV patients [ 24 , 25 , 26 , 27 , 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

“…Various studies have shown that liquid biopsy can be used to detect mutated BRAF, which can be identified in 32% of stage I/II patients and 39% of stage III/IV patients [ 24 , 25 , 26 , 27 , 28 , 29 ]. Patients with BRAFV600 -mutant tumors can be treated with highly effective BRAF plus MEK -targeted therapies (dabrafenib/trametinib, vemurafenib/cobimetinib, and encorafenib/binimetinib) with significant overall survival benefits [ 23 ]. Assessment of BRAFV600 mutant circulating cell-free tumor DNA could be a tool for therapeutic monitoring in BRAFV600 mutant metastatic melanoma patients treated with BRAF/MEK inhibitors, since a relationship has been shown between this ctDNA, durable responses, and survival outcomes [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples

Gumà

Peña

Riu

et al. 2022

Cancers

View full text Add to dashboard Cite

Liquid biopsy has improved significantly over the last decade and is attracting attention as a tool that can complement tissue biopsy to evaluate the genetic landscape of solid tumors. In the present study, we evaluated the usefulness of liquid biopsy in daily oncology practice in different clinical contexts. We studied ctDNA and tissue biopsy to investigate EGFR, KRAS, NRAS, and BRAF mutations from 199 cancer patients between January 2016 and March 2021. The study included 114 male and 85 female patients with a median age of 68 years. A total of 122 cases were lung carcinoma, 53 were colorectal carcinoma, and 24 were melanoma. Liquid biopsy was positive for a potentially druggable driver mutation in 14 lung and colorectal carcinoma where tissue biopsy was not performed, and in two (3%) lung carcinoma patients whose tissue biopsy was negative. Liquid biopsy identified nine (45%) de novo EGFR-T790M mutations during TKI-treatment follow-up in lung carcinoma. BRAF-V600 mutation resurgence was detected in three (12.5%) melanoma patients during follow-up. Our results confirm the value of liquid biopsy in routine clinical oncologic practice for targeted therapy, diagnosis of resistance to treatment, and cancer follow-up.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples

Gumà

Peña

Riu

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Dear Editor, Liquid biopsy has attracted attention recently in various pathological conditions such as cancers 1 and inflammatory diseases. 2 Exosomes have gained attention for their significance in liquid biopsies because they are present in body fluids with high stability. 2 Exosomes are extracellular nanovesicles with diameters of 30-150 nm and contain microRNAs, messenger RNAs (mRNAs), DNA, proteins, and lipids.…”

Section: Increased Circulating Exosomal Janus Kinase 2 Messenger Rna ...mentioning

confidence: 99%

“…2 Exosomes have gained attention for their significance in liquid biopsies because they are present in body fluids with high stability. 2 Exosomes are extracellular nanovesicles with diameters of 30-150 nm and contain microRNAs, messenger RNAs (mRNAs), DNA, proteins, and lipids. The clinical significance of exosomes as biomarkers has been established for several skin diseases, including psoriasis.…”

Section: Increased Circulating Exosomal Janus Kinase 2 Messenger Rna ...mentioning

confidence: 99%

Increased circulating exosomal Janus kinase 2 messenger RNA levels in psoriasis

Shimada

Myangat

Kajihara

et al. 2023

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

“…6 miRNAs are a class of small non-coding RNAs with an average length of 20-24 nucleotides that usually bind to 3 0 -untranslated regions (UTR) of target mRNA genes, leading to gene silencing. 7 In tumour tissues, some lowly expressed miRNAs act as tumour suppressors by negatively regulating oncogenes, while some highly expressed miRNAs act as oncogenes by suppressing the tumour suppressor genes. 8 Numerous dysregulated miRNAs are crucial for cell migration, apoptosis, carcinogenesis, metastasis, cellular growth, and cell cycle regulation.…”

mentioning

confidence: 99%

Elevated expression of miR‐301a and its functional roles in canine oral melanoma

Hasan,

Rahman,

Husna

et al. 2023

Vet Comparative Oncology

View full text Add to dashboard Cite

AbstractmiR‐301a is one of numerous dysregulated microRNAs (miRNAs) in canine oral melanoma (COM), one of which is miR‐301a (upregulated). Its biological role has been described in various human cancer types, including malignant melanoma, but not in COM. Accordingly, in this study, we investigated miR‐301a expression in COM in greater detail to ascertain whether it could serve as a diagnostic biomarker, elucidate its functional roles in this cancer, and predict the possible pathways by which it exerts its effects. Relative expression of miR‐301a was investigated in clinical oral tissue and plasma samples and COM cell (KMeC and LMeC) lines using qRT‐PCR. Knockdown of miR‐301a was also validated for KMeC and LMeC cells using qRT‐PCR. We performed CCK‐8 assays to assess cell proliferation, monolayer wound‐healing, and transwell migration assays to assess cell migration, a colony‐formation assay to assess clonogenicity, a TUNEL assay and flow cytometry to assess apoptosis‐related effects, and gene enrichment analyses to predict possible related pathways. miR‐301a was markedly upregulated in COM oral tissue and plasma clinically, suggesting its potential as a diagnostic biomarker for COM diagnosis. In vitro assays demonstrated that miR‐301 significantly inhibited apoptosis in COM cells while promoting cell migration, proliferation, and clonogenicity. We also predicted that miR‐301 exerts cancer‐promoting effects through the Wnt signalling pathway for COM. Our findings suggest that miR‐301a is a COM oncomiR that regulates several oncogenic phenotypes with the potential to be a diagnostic biomarker.

show abstract

Promising Blood-Based Biomarkers for Melanoma: Recent Progress of Liquid Biopsy and Its Future Perspectives

Cited by 8 publications

References 94 publications

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples

Increased circulating exosomal Janus kinase 2 messenger RNA levels in psoriasis

Elevated expression of miR‐301a and its functional roles in canine oral melanoma

Contact Info

Product

Resources

About